Tag: Mental Health

VistaGen advances fasedienol’s Phase 3 PALISADE-3 toward data in late 2025, while PALISADE-4 continues enrollment, extending its CNS innovation momentum.

Vistagen’s late-stage CNS pipeline, led by fasedienol™, shows clinical progress and strategic growth despite liquidity pressures and non-material revenue.

Vistagen Therapeutics is making breakthroughs in CNS treatments with PH94B, PH10, and AV-101, offering new hope for anxiety and depression patients.

Discover how VistaGen's cutting-edge Pherine technology transforms treatment for anxiety, depression, and CNS disorders, promising faster, safer therapies.